NZ629122A - Liver x receptor modulators - Google Patents

Liver x receptor modulators

Info

Publication number: NZ629122A
Authority: NZ; New Zealand
Prior art keywords: liver; compounds; receptor modulators; imidazo; compositions
Prior art date: 2012-03-16

Application number

NZ629122A

Other languages

English (en)

Inventor

Chengguo Dong

Yi Fan

Katerina Leftheris

Stephen Lotesta

Suresh B Singh

Colin Tice

Wei Zhao

Yajun Zheng

Linghang Zhuang

Original Assignee

Vitae Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-16

Filing date

2013-03-14

Publication date

2016-04-29

2013-03-14 Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc

2016-04-29 Publication of NZ629122A publication Critical patent/NZ629122A/en

Links

102000004311 liver X receptors Human genes 0.000 title abstract 3
108090000865 liver X receptors Proteins 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
CVGPZQMGLKRVJV-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazole Chemical class C1=CC=C2N3CCNCC3=NC2=C1 CVGPZQMGLKRVJV-UHFFFAOYSA-N 0.000 abstract 1
AEIDURNZWCNQIM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical class C1=CC=C2N3CCNCC3=CC2=C1 AEIDURNZWCNQIM-UHFFFAOYSA-N 0.000 abstract 1
CABUZECPUSGGRX-QGZVFWFLSA-N [(1r)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1h-pyrazino[1,2-a]benzimidazol-8-yl]methanol Chemical compound N1([C@@H](C=2N(C3=CC(=C(CO)C=C3N=2)S(C)(=O)=O)CC1)C(C)C)C1=NC=CC(C(F)(F)F)=N1 CABUZECPUSGGRX-QGZVFWFLSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)

NZ629122A 2012-03-16 2013-03-14 Liver x receptor modulators NZ629122A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261612051P	2012-03-16	2012-03-16
PCT/US2013/031242 WO2013138565A1 (en)	2012-03-16	2013-03-14	Liver x receptor modulators

Publications (1)

Publication Number	Publication Date
NZ629122A true NZ629122A (en)	2016-04-29

Family

ID=47997957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ629122A NZ629122A (en)	2012-03-16	2013-03-14	Liver x receptor modulators

Country Status (27)

Country	Link
US (4)	US9006244B2 (2)
EP (1)	EP2825541B1 (2)
JP (3)	JP6114814B2 (2)
KR (1)	KR102069912B1 (2)
CN (1)	CN104203951B (2)
AU (1)	AU2013232066B2 (2)
CA (1)	CA2866218C (2)
CY (1)	CY1118318T1 (2)
DK (1)	DK2825541T3 (2)
EA (1)	EA026907B1 (2)
ES (1)	ES2598653T3 (2)
HR (1)	HRP20161196T1 (2)
HU (1)	HUE029402T2 (2)
IL (1)	IL234265B (2)
IN (1)	IN2014DN07636A (2)
LT (1)	LT2825541T (2)
ME (1)	ME02534B (2)
MX (1)	MX354818B (2)
NZ (1)	NZ629122A (2)
PL (1)	PL2825541T3 (2)
PT (1)	PT2825541T (2)
RS (1)	RS55166B1 (2)
SG (1)	SG11201405328SA (2)
SI (1)	SI2825541T1 (2)
SM (1)	SMT201600374B (2)
WO (1)	WO2013138565A1 (2)
ZA (1)	ZA201406326B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104203951B (zh) *	2012-03-16	2016-11-02	生命医药公司	肝x受体调节剂
WO2013138568A1 (en) *	2012-03-16	2013-09-19	Vitae Pharmaceuticals, Inc.	Liver x reception modulators
WO2015106164A1 (en)	2014-01-10	2015-07-16	Rgenix, Inc.	Lxr agonists and uses thereof
WO2015195922A1 (en) *	2014-06-19	2015-12-23	Vitae Pharmaceuticals, Inc.	Compounds for use in treating acute coronary syndrome and related conditions
BR112017002260A2 (pt) *	2014-08-07	2017-11-21	Vitae Pharmaceuticals Inc	derivados de piperazina como moduladores do receptor x do fígado
US20190125745A1 (en) *	2014-12-17	2019-05-02	Rgenix, Inc.	Treatment and diagnosis of cancer
CN105017262B (zh) *	2015-07-07	2017-05-03	广东也乐新材料制造有限公司	一种醛基取代多环杂芳烃化合物的合成方法
CN105288658B (zh) *	2015-10-30	2018-08-28	中国人民解放军第三军医大学	miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用
EP3402477A4 (en)	2016-01-11	2019-08-21	The Rockefeller University	METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS
CA3078981A1 (en)	2017-11-21	2019-05-31	Rgenix, Inc.	Polymorphs and uses thereof
TWI888447B (zh)	2019-12-13	2025-07-01	美商因思博納公司	金屬鹽及其用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4748247A (en)	1986-10-21	1988-05-31	American Home Products Corporation	2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
CA2074163A1 (en)	1990-01-22	1991-07-23	William Thomas Zimmerman	Herbicidal sulfonylureas
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
CA2179650C (en)	1993-12-23	2007-10-30	William Francis Heath, Jr.	Bisindolemaleimides and their use as protein kinase c inhibitors
US5545636A (en)	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
AU3831495A (en)	1994-10-20	1996-05-15	American Home Products Corporation	Indole derivatives useful as serotonergic agents
US5854245A (en)	1996-06-28	1998-12-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
AU709631B2 (en)	1996-06-28	1999-09-02	Merck & Co., Inc.	Fibrinogen receptor antagonist prodrugs
JP2000513375A (ja)	1996-06-28	2000-10-10	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプター拮抗薬プロドラッグ
WO1998000134A1 (en)	1996-06-28	1998-01-08	Merck & Co., Inc.	Fibrinogen receptor antagonists
US6177440B1 (en)	1996-10-30	2001-01-23	Eli Lilly And Company	Substituted tricyclics
FR2761070B1 (fr)	1997-03-20	1999-04-23	Synthelabo	Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761073B1 (fr) *	1997-03-20	1999-04-23	Synthelabo	Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de)	1998-01-22	1999-07-29	Bayer Ag	Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en)	1998-04-17	2000-02-29	Lilly Co Eli	Substituted tricyclics
DE60018274T2 (de)	1999-05-06	2005-08-04	Neurogen Corp., Branford	Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
US7037916B2 (en)	1999-07-15	2006-05-02	Pharmacopeia Drug Discovery, Inc.	Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it)	1999-08-03	2002-09-09	Novuspharma Spa	Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en)	1999-10-22	2001-05-03	Eli Lilly And Company	Therapeutic compositions including protein kinase c inhibitors
DE60132975T2 (de)	2000-01-06	2009-02-26	Merck Frosst Canada Inc., Kirkland	Neue substanzen und verbindungen als protease-inhibitoren
JP4180365B2 (ja)	2000-07-31	2008-11-12	エフ．ホフマン−ラロシュアーゲー	ピペラジン誘導体
EP1343768A1 (en)	2000-12-20	2003-09-17	Bristol-Myers Squibb Pharma Company	Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) *	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
FR2829766A1 (fr)	2001-09-14	2003-03-21	Lipha	Derives d'oxamates comportant un heterocycle azote diversement substitue
CA2471562A1 (en)	2001-12-21	2003-07-24	King Pharmaceuticals Research And Development, Inc.	Tyrosyl derivatives and their use as p2x7 receptor modulators
US7919497B2 (en)	2002-08-02	2011-04-05	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de)	2003-05-09	2005-01-20	Bayer Healthcare Ag	Heterocyclyl-substituierte Dihydrochinazoline
US7994196B2 (en)	2004-02-12	2011-08-09	Mitsubishi Tanabe Pharma Corporation	Indazole compound and pharmaceutical use thereof
BRPI0509754A (pt)	2004-04-08	2007-10-16	Novartis Ag	inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante
RU2266906C1 (ru)	2004-04-29	2005-12-27	Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия")	Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it)	2004-04-30	2004-07-30	Ist Naz Stud Cura Dei Tumori	Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en)	2004-05-21	2005-12-01	Pfizer Products Inc.	Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
ATE457989T1 (de) *	2004-12-15	2010-03-15	Hoffmann La Roche	Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
WO2006072608A2 (en)	2005-01-03	2006-07-13	Universitá Degli Studi Di Siena	Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en)	2005-03-17	2010-09-07	Boehringer Ingelheim Pharmaceutical, Inc.	Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en)	2005-04-07	2006-10-12	Pfizer Inc.	Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
CA2615726C (en)	2005-07-14	2014-05-27	Caterina Bissantz	Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
WO2007035841A1 (en)	2005-09-21	2007-03-29	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en)	2005-10-28	2007-05-02	Nikem Research S.R.L.	V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP2007137810A (ja) *	2005-11-17	2007-06-07	Sankyo Co Ltd	インドール化合物を含有する医薬
DE602006010433D1 (de)	2005-12-09	2009-12-24	Hoffmann La Roche	Für die behandlung von obesitas geeignete tricyclische amidderivate
US7351706B2 (en)	2006-01-05	2008-04-01	Hoffmann-La Roche Inc.	Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) *	2006-02-03	2010-09-03	Sanofi Aventis	Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru)	2006-04-12	2008-03-10	Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия"	Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en)	2006-11-03	2012-03-06	Nereus Pharmacuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
WO2008122115A1 (en)	2007-04-09	2008-10-16	Methylgene Inc.	Inhibitors of histone deacetylase
CA2690748A1 (en)	2007-06-25	2008-12-31	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2205085A1 (en)	2007-09-25	2010-07-14	Merck Sharp & Dohme Corp.	2-aryl or heteroaryl indole derivatives
CN101456863B (zh) *	2007-12-14	2012-04-25	华北制药集团新药研究开发有限责任公司	Lxr激动剂及其制备方法和用途
US20100324073A1 (en) *	2007-12-21	2010-12-23	Wyeth Llc	Pyrazolo [1,5-A] Pyrimidine Compounds
PE20091439A1 (es)	2008-01-22	2009-10-19	Takeda Pharmaceutical	Compuestos triciclicos como antagonistas de crf
US20090192147A1 (en)	2008-01-30	2009-07-30	Wyeth	[a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100137320A1 (en)	2008-02-29	2010-06-03	Schering Corporation	Gamma secretase modulators
EP2254886B1 (en)	2008-03-28	2016-05-25	Nerviano Medical Sciences S.r.l.	3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en)	2009-02-04	2010-09-01	Gruenenthal Gmbh	Substituted indole-compound
AU2010257856A1 (en)	2009-06-08	2011-11-03	Grünenthal GmbH	Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2011005295A1 (en)	2009-06-24	2011-01-13	Arena Pharmaceuticals, Inc.	Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
MX2012002898A (es)	2009-09-11	2012-04-02	Sunovion Pharmaceuticals Inc	Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
WO2011071725A1 (en)	2009-12-07	2011-06-16	Boehringer Ingelheim International Gmbh	Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US20130045203A1 (en)	2010-03-02	2013-02-21	Emory University	Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
US8654867B2 (en)	2011-12-07	2014-02-18	Texas Instruments Incorporated	Transformer power combiner with filter response
WO2013138568A1 (en) *	2012-03-16	2013-09-19	Vitae Pharmaceuticals, Inc.	Liver x reception modulators
CN104203951B (zh) *	2012-03-16	2016-11-02	生命医药公司	肝x受体调节剂

2013
- 2013-03-14 CN CN201380014354.5A patent/CN104203951B/zh not_active Expired - Fee Related
- 2013-03-14 US US14/385,688 patent/US9006244B2/en active Active
- 2013-03-14 DK DK13712102.6T patent/DK2825541T3/en active
- 2013-03-14 ES ES13712102.6T patent/ES2598653T3/es active Active
- 2013-03-14 SI SI201330303A patent/SI2825541T1/sl unknown
- 2013-03-14 SG SG11201405328SA patent/SG11201405328SA/en unknown
- 2013-03-14 RS RS20160785A patent/RS55166B1/sr unknown
- 2013-03-14 AU AU2013232066A patent/AU2013232066B2/en not_active Ceased
- 2013-03-14 IN IN7636DEN2014 patent/IN2014DN07636A/en unknown
- 2013-03-14 KR KR1020147028754A patent/KR102069912B1/ko not_active Expired - Fee Related
- 2013-03-14 JP JP2015500602A patent/JP6114814B2/ja not_active Expired - Fee Related
- 2013-03-14 EP EP13712102.6A patent/EP2825541B1/en active Active
- 2013-03-14 MX MX2014011103A patent/MX354818B/es active IP Right Grant
- 2013-03-14 WO PCT/US2013/031242 patent/WO2013138565A1/en not_active Ceased
- 2013-03-14 NZ NZ629122A patent/NZ629122A/en not_active IP Right Cessation
- 2013-03-14 HU HUE13712102A patent/HUE029402T2/en unknown
- 2013-03-14 PT PT137121026T patent/PT2825541T/pt unknown
- 2013-03-14 CA CA2866218A patent/CA2866218C/en not_active Expired - Fee Related
- 2013-03-14 PL PL13712102.6T patent/PL2825541T3/pl unknown
- 2013-03-14 EA EA201491609A patent/EA026907B1/ru unknown
- 2013-03-14 LT LTEP13712102.6T patent/LT2825541T/lt unknown
- 2013-03-14 HR HRP20161196TT patent/HRP20161196T1/hr unknown
- 2013-03-14 ME MEP-2016-211A patent/ME02534B/me unknown
2014
- 2014-08-24 IL IL234265A patent/IL234265B/en active IP Right Grant
- 2014-08-27 ZA ZA201406326A patent/ZA201406326B/en unknown
- 2014-11-19 US US14/547,804 patent/US9006245B2/en active Active
2015
- 2015-03-13 US US14/657,179 patent/US9388190B2/en active Active
2016
- 2016-06-15 US US15/182,749 patent/US9814715B2/en active Active
- 2016-09-22 CY CY20161100948T patent/CY1118318T1/el unknown
- 2016-10-14 SM SM201600374T patent/SMT201600374B/it unknown
2017
- 2017-03-14 JP JP2017048432A patent/JP2017128588A/ja active Pending
2018
- 2018-09-14 JP JP2018172260A patent/JP2019023196A/ja active Pending

Also Published As

Publication number	Publication date
AU2013232066B2 (en)	2017-07-06
US9814715B2 (en)	2017-11-14
HRP20161196T1 (hr)	2016-11-04
JP2015510892A (ja)	2015-04-13
PT2825541T (pt)	2016-09-28
CA2866218A1 (en)	2013-09-19
US20150080406A1 (en)	2015-03-19
US20170136017A1 (en)	2017-05-18
EP2825541A1 (en)	2015-01-21
HK1206333A1 (en)	2016-01-08
JP2019023196A (ja)	2019-02-14
MX2014011103A (es)	2014-12-05
HUE029402T2 (en)	2017-02-28
EP2825541B1 (en)	2016-06-22
MX354818B (es)	2018-03-21
ME02534B (me)	2017-02-20
SI2825541T1 (sl)	2016-10-28
IL234265B (en)	2020-06-30
US20150051214A1 (en)	2015-02-19
WO2013138565A1 (en)	2013-09-19
ES2598653T3 (es)	2017-01-30
PL2825541T3 (pl)	2016-12-30
US20150246924A1 (en)	2015-09-03
AU2013232066A1 (en)	2014-09-11
KR102069912B1 (ko)	2020-01-23
SG11201405328SA (en)	2014-11-27
US9006244B2 (en)	2015-04-14
RS55166B1 (sr)	2017-01-31
LT2825541T (lt)	2016-12-27
DK2825541T3 (en)	2016-10-03
JP6114814B2 (ja)	2017-04-12
CY1118318T1 (el)	2017-06-28
CA2866218C (en)	2020-06-09
IN2014DN07636A (2)	2015-05-15
US9388190B2 (en)	2016-07-12
ZA201406326B (en)	2019-11-27
EA026907B1 (ru)	2017-05-31
CN104203951B (zh)	2016-11-02
CN104203951A (zh)	2014-12-10
EA201491609A1 (ru)	2014-12-30
SMT201600374B (it)	2016-11-10
US9006245B2 (en)	2015-04-14
JP2017128588A (ja)	2017-07-27
KR20140139555A (ko)	2014-12-05

Legal Events

Date	Code	Title	Description
2016-08-26	PSEA	Patent sealed
2017-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY CPA GLOBAL Effective date: 20170127
2018-01-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY CPA GLOBAL Effective date: 20180125
2019-02-22	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190219
2020-02-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200218
2021-03-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY COMPUTER PACKAGES INC Effective date: 20210306
2022-09-30	LAPS	Patent lapsed

Publication	Publication Date	Title
NZ629122A (en)	2016-04-29	Liver x receptor modulators
NZ629189A (en)	2016-08-26	Liver x receptor modulators
CY2020006I2 (el)	2020-11-25	Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk
NZ630721A (en)	2016-12-23	Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
NZ626394A (en)	2016-11-25	Substituted annulated pyrimidines and triazines, and use thereof
EA201290147A1 (ru)	2012-11-30	Пирроло[2,3-d]пиримидиновые соединения
PE20090596A1 (es)	2009-06-07	Imidazoles biciclicos fusionados
MX2013007148A (es)	2013-11-01	2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina.
EA201390199A1 (ru)	2013-07-30	2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
EA201170769A1 (ru)	2012-02-28	Органические соединения
NZ590777A (en)	2012-11-30	PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
EA201170771A1 (ru)	2012-01-30	Органические соединения
MX2012009074A (es)	2012-08-23	Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
PH12013502020A1 (en)	2018-04-11	Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
NZ703111A (en)	2016-07-29	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
NZ629442A (en)	2016-12-23	Heterocyclyl compounds as mek inhibitors
NZ627454A (en)	2016-09-30	2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
NZ702571A (en)	2017-02-24	4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
MX2013013294A (es)	2014-04-25	Inhibidores de tirosina-cinasas.
NZ630719A (en)	2017-01-27	Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
TN2011000244A1 (en)	2012-12-17	Organic compounds
AU2014270524A8 (en)	2015-09-24	2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MX370814B (es)	2020-01-08	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
TN2018000087A1 (en)	2019-07-08	New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
WO2014063054A8 (en)	2014-06-19	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof